GRTXD · Galera Therapeutics, Inc. · Shareholders & Ownership
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about our ability to continue as a going concern through the 12 months from the date of the filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed May 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Every disclosed holder of GRTXD in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns GRTXD
13F quarter Mar 31, 2026| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 0 | 0.00% |
| Insiders (Forms 3, 4, 5) | 305,150 | 38.04% |
| 13D/G-only blocks | 123,666 | 15.42% |
| Remaining | 373,333 | 46.54% |
| Registered funds (N-PORT, not summed) | 0 | 0.00% |
Shares outstanding: 802,149, the issuer's latest cover-page count restated onto today's split basis.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of GRTXD
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
|
305,150 | ||
| 1.1 |
|
305,150 | ||
| 2 |
Parvinder Singh Hyare
13D
CIK 1838253 · Unknown · May 15, 2026
Item 4 purpose: Merger opposition or support, Other
|
67,610 | ||
| 3 |
|
11,448 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.